Concepedia

Publication | Closed Access

Cancer Risk After Use of Recombinant Bone Morphogenetic Protein-2 for Spinal Arthrodesis

DOI

257

Citations

20

References

2013

Year

Eugene J. Carragee, Gilbert Chu, Rajat Rohatgi, Eric L. Hurwitz, Bradley K. Weiner, S. Tim Yoon, Garet C. Comer, Branko Kopjar
Journal of Bone and Joint Surgery

Abstract

A high dose of 40 mg of rhBMP-2/CRM in lumbar spinal arthrodesis was associated with an increased risk of new cancer.

References

YearCitations

Page 1